The Bigger the Ship, the Harder It Is to Turn: Continued Clinical Inertia With SGLT2i Utilization in Heart Failure

被引：0
|
作者：
Lyle, Melissa [1 ]
Santos-Gallego, Carlos G. [2 ]
机构：
[1] Mayo Clin, Div Adv Heart Failure & Transplant Cardiol, Jacksonville, FL 32224 USA
[2] Icahn Sch Med Mt Sinai, Cardiovasc Inst, Athero Thrombosis Res Unit, New York, NY USA
来源：
JOURNAL OF CARDIAC FAILURE | 2024年 / 30卷 / 09期
关键词：
EMPAGLIFLOZIN; OUTCOMES;
D O I：
10.1016/j.cardfail.2024.05.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1098 / 1099
页数：2
相关论文
共 41 条
  • [21] Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure
    Galli, Mattia
    D'Amario, Domenico
    Sofia, Carmelo
    Vaccarella, Marcello
    Crea, Filippo
    Aspromonte, Nadia
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (12) : 1273 - 1285
  • [22] SGLT2 Inhibitors in Heart Failure Early Initiation to Achieve Rapid Clinical Benefits
    Dixit, Neal M.
    Ziaeian, Boback
    Fonarow, Gregg C.
    HEART FAILURE CLINICS, 2022, 18 (04) : 587 - 596
  • [23] Representation of women and racial minorities in SGLT2 inhibitors and heart failure clinical trials
    Gupta, Rahul
    Umeh, Chukwuemeka
    Mohta, Tamanna
    Vaidya, Ajay
    Wolfson, Aaron
    Nattiv, Jonathan
    Bhatia, Harpreet
    Kaur, Gagan
    Dhawan, Raghav
    Darji, Puja
    Eghreriniovo, Benson
    Sanwo, Eseosa
    Hotwani, Priya
    Mahdavian, Payaam
    Kumar, Sabina
    Tiwari, Bhoodev
    IJC HEART & VASCULATURE, 2024, 55
  • [24] Sodium-glucose co-transporter 2 inhibitors (SGLT2i); as a preventive factor of kidney failure in patients with type 2 diabetes; a meta-analysis of randomized controlled trials
    Jahangiri, Dorsa
    Padhi, Udit Narayan
    Verma, Henu Kumar
    Lakkakula, Bhaskar V. K. S.
    Valizadeh, Rohollah
    Nasri, Hamid
    JOURNAL OF RENAL INJURY PREVENTION, 2021, 10 (04): : 1 - 8
  • [25] The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review
    Ezhumalai, Babu
    Modi, Ranjan
    Panchanatham, Manokar
    Kaliyamoorthy, Dhamodaran
    INDIAN HEART JOURNAL, 2024, 76 (04) : 229 - 239
  • [26] Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?
    Xu, Dan
    Chandler, Owain
    Wee, Cleo
    Ho, Chau
    Affandi, Jacquita S.
    Yang, Daya
    Liao, Xinxue
    Chen, Wei
    Li, Yanbing
    Reid, Christopher
    Xiao, Haipeng
    FRONTIERS IN MEDICINE, 2021, 8
  • [27] Association of Initiating SGLT2i and GLP1Ra Therapeutics on Insulin Utilization and MACE Outcomes Among Patients With Diabetes in an Integrated Healthcare System
    Le, Viet T.
    May, Heidi T.
    Bair, Tami L.
    Knight, Stacey
    Horne, Benjamin D.
    Knowlton, Kirk U.
    Anderson, Jeffrey L.
    CIRCULATION, 2023, 148
  • [28] Use of i-SGLT2 in patients with type 2 Diabetes Mellitus, cardiovascular disease and heart failure: what evidence do we have available?
    Martinez, Felipe
    Garcia Brasca, Daniela F.
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2020, 49 : 19 - 23
  • [29] Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure
    Vaduganathan, Muthiah
    Greene, Stephen J.
    Zhang, Shuaiqi
    Solomon, Nicole
    Chiswell, Karen
    Devore, Adam D.
    Butler, Javed
    Heidenreich, Paul A.
    Huang, Joanna C.
    Kittleson, Michelle M.
    Maddox, Karen E. Joynt
    Mcdermott, James J.
    Owens, Anjali Tiku
    Peterson, Pamela N.
    Solomon, Scott D.
    Vardeny, Orly
    Yancy, Clyde W.
    Fonarow, Gregg C.
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (04) : 554 - 563
  • [30] Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure
    Cromer, Sara J.
    Lauffenburger, Julie C.
    Levin, Raisa
    Patorno, Elisabetta
    DIABETES CARE, 2023, 46 (01) : 65 - 74
12345